MET and non-small cell lung carcinoma: Accordingly, in the setting of EGFR-mutated NSCLC progressing on EGFR-TKIs, acquired resistance to EGFR-TKIs due to activation of the parallel bypass MET-signaling pathway is typically associated with high-level MET amplification [4,5].